



Article

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

Michael Morris ¹, Richard Chye ² , Zhixin Liu ³, Meera Agar ^{1,4,5} and Valentina Razmovski-Naumovski ^{1,2,4,5,*} 

¹ South West Sydney Clinical Campuses, Faculty of Medicine & Health, University of New South Wales Sydney (UNSW), Sydney, NSW 2170, Australia

² Sacred Heart Health Service, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia

³ Stats Central, University of New South Wales Sydney (UNSW), Sydney, NSW 2170, Australia

⁴ Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia

⁵ Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia

* Correspondence: v.naumovski@unsw.edu.au

Abstract: Research describing patients using medicinal cannabis and its effectiveness is lacking. We aimed to describe adults with non-cancer diagnoses who are prescribed medicinal cannabis via a retrospective medical record review and assess its effectiveness and safety. From 157 Australian records, most were female (63.7%; mean age 63.0 years). Most patients had neurological (58.0%) or musculoskeletal (24.8%) conditions. Medicinal cannabis was perceived beneficial by 53.5% of patients. Mixed-effects modelling and post hoc multiple comparisons analysis showed significant changes overtime for pain, bowel problems, fatigue, difficulty sleeping, mood, quality of life (all $p < 0.0001$), breathing problems ($p = 0.0035$), and appetite ($p = 0.0465$) Symptom Assessment Scale scores. For the conditions, neuropathic pain/peripheral neuropathy had the highest rate of perceived benefit (66.6%), followed by Parkinson's disease (60.9%), multiple sclerosis (60.0%), migraine (43.8%), chronic pain syndrome (42.1%), and spondylosis (40.0%). For the indications, medicinal cannabis had the greatest perceived effect on sleep (80.0%), followed by pain (51.5%), and muscle spasm (50%). Oral oil preparations of balanced delta-9-tetrahydrocannabinol/cannabidiol (average post-titration dose of 16.9 mg and 34.8 mg per day, respectively) were mainly prescribed. Somnolence was the most frequently reported side effect (21%). This study supports medicinal cannabis' potential to safely treat non-cancer chronic conditions and indications.

Keywords: medicinal cannabis; conditions; indications; non-cancer; pain; retrospective review; symptoms



Citation: Morris, M.; Chye, R.; Liu, Z.; Agar, M.; Razmovski-Naumovski, V. A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis. *J. Clin. Med.* **2023**, *12*, 1483. <https://doi.org/10.3390/jcm12041483>

Academic Editors: Michael Froelich and Markus W. Hollmann

Received: 6 December 2022

Revised: 27 January 2023

Accepted: 3 February 2023

Published: 13 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cannabis (Cannabaceae) has been used medicinally since 400 AD for its analgesic, appetite enhancement, and myorelaxant properties [1–3]. Emerging evidence suggests that people with chronic conditions may benefit from using medicinal cannabis for treating chronic pain, multiple sclerosis-related spasticity, epilepsy, Parkinson's disease, insomnia, and anxiety [4]. However, evidence supporting medicinal cannabis for these conditions/symptoms is generally anecdotal and inconclusive [5]. Limitations include short study durations, small sample sizes, differing formulations/modes of administration, lack of follow-up [4], and stigma surrounding its addiction and abuse [6].

In Australia, impressive public support instigated legislative changes in 2016 allowing medical doctors to prescribe cannabis-based medicines for chronically ill patients subject to the approval from the Therapeutic Goods Administration [7] which is the medicine and therapeutic regulatory agency of the Australian Government. Unregistered cannabis-based medicines can be prescribed through the TGA Special Access Scheme, in particular, Category B (SAS Cat-B) [8], and this requires clinical justification for patient use, reasons why registered medications have not been appropriate, and the expected benefits versus

harms of the proposed treatment; or Authorized Prescriber Program (using medicines with an established history of use) [9]. In addition, doctors will assess any problems with drug dependence and substance abuse. In Australia, there has been exponential growth in the use of medicinal cannabis: by 2021, over 333,000 SAS Cat-B approvals had been issued to patients and over 1807 authorized prescribers, which shows the growing interest in legally prescribed medicinal cannabis [8,9].

Rapidly increasing public interest in medicinal cannabis necessitates research into the conditions/symptoms it can potentially treat, and its safety profile and this has prompted the Australian government to fund clinical trials to ascertain its place in mainstream medicine [10]. Whilst we wait for these results, retrospective studies assist in understanding benefits and harms in real-world clinical practice and provide data to guide future clinical trials [11]. There are few retrospective studies that report on all facets of medicinal cannabis use including demographics, perceived efficacy, cannabis formulations, and side effects.

This retrospective study will aim to answer the questions: (1) What are the characteristics of people with non-cancer diagnoses using medicinal cannabis? and (2) Does medicinal cannabis provide effective relief for patient conditions and symptoms? Secondary objectives include determining dosage, side effects, and reasons for cessation of treatment.

2. Methods

2.1. Study Design, Setting, and Population

A retrospective medical record review was conducted at Wolper Jewish Hospital in Sydney, Australia, which is a stand-alone, not-for-profit clinic specializing in rehabilitation and palliative care. A consent form was provided which talks about the risk of psychosis and schizophrenia. Medical records of patients prescribed medicinal cannabis between 1 February 2018 and 30 November 2021 were reviewed using the inclusion criteria: (1) 18 years or older; and (2) non-cancer diagnosis. This study was approved by the St Vincent's Hospital Sydney Human Research Ethics Committee (Approval No: 2020ETH00008).

2.2. Characteristics Retrieved

Patient demographic data (age, gender, postcode, country of birth, indigenous status, and marital status), medical data (condition(s), primary and secondary indication(s)), administration route, cannabinoid ratio, dose, number of cannabis-based medicine(s), and previous cannabis use were recorded. Side effects, treatment continuation, and reasons for cessation were quantitatively described.

2.3. Evaluation of Effectiveness

The effectiveness of medicinal cannabis treatment was examined by the following: (1) The patient's own perceived benefit reported as 'beneficial', 'not beneficial' or 'unclear'; this data was used as a proxy to determine overall and condition-specific perceived benefit. (2) The Palliative Care Outcomes Collaboration (PCOC) Symptom Assessment Scale (SAS) scores. This validated tool reliably measures patient-reported symptom distress amongst those with advanced disease and includes pain, fatigue, breathing problems, bowel problems, appetite, nausea, difficulty sleeping, and mood. Each symptom is rated out of 10 (0 = not at all to 10 = worst possible). Scores 0–3 depict mild distress, 4–7 moderate distress, and 8–10 severe distress [12]. Patients also rated their quality of life (QoL) out of 10 (0 = worst possible to 10 = best possible). Pre-treatment SAS scores were recorded at 5–6 weeks, 3, 6, 9, 12 months, etc., depending on patients' clinic attendance.

2.4. Statistical Analysis

De-identified patient data were entered into an Excel spreadsheet and analyzed descriptively. To account for missing data, patient scores for each SAS symptom were grouped into baseline and three-month blocks, averaged, and analyzed by fitting a mixed-effects model [13]. Post hoc multiple comparisons analysis using Dunnett's test identified the statistical significance of timepoints compared to baseline. Analysis was stopped at the timepoint

which had around 50% of the initial patient cohort for each condition or symptom. Cohorts with low patient numbers were analyzed with a Wilcoxon signed-rank test. Two-tailed *t*-test compared the highest doses of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ -9-THC). Statistical significance was set at $p < 0.05$. Statistical tests were performed using GraphPad Prism (v9.1.2, GraphPad Software Inc., San Diego, CA, USA).

3. Results

3.1. Characteristics of the Included Patients

Two-hundred-and-seven patients met the study inclusion criteria. Fifty patients were excluded due to missing files/poor data, resulting in 157 patients analyzed.

Patients were predominantly female (63.7%), aged 63.0 years, and from the Greater Sydney region (86.6%). Most patients were born in Australia (66.9%) and partnered (57.3%), with 17.8% stating previous cannabis use (Table 1).

Patients reported an array of conditions (Table S1) and indications (Table S2) treated with medicinal cannabis. Primarily, patients (87.3%) reported one condition which fell under the neurological (58.0%) and musculoskeletal class (24.8%). The most common patient indications included pain (86.6%), muscle spasm (11.5%), and sleep (6.4%) (Table 1).

Patients were mostly prescribed one cannabis-based medicine (CBM; 71.3%), an oral oil CBM (99.4%) with balanced Δ -9-THC and CBD (84.7%). The mean highest CBD dose (34.8 ± 48.04 mg/day) was significantly higher ($p < 0.0001$) than Δ -9-THC (16.9 ± 17.23 mg/day) (Table 1).

Table 1. Clinical characteristics of adults prescribed medicinal cannabis at the clinic.

Characteristics	Number of Patients (%) ($n = 157$)
Age (years)	
Mean \pm standard deviation	63.0 \pm 16.0
Range	18–100
Over 40 years	141 (89.8)
Under 65 years	75 (47.8)
65 years and over	82 (52.2)
Gender ^a	
Male	57 (36.3)
Female	100 (63.7)
Place of residence	
Greater Sydney Region ^b	136 (86.6)
Non-Sydney NSW	17 (10.8)
Queensland	1 (0.6)
Australian Capital Territory	1 (0.6)
Tasmania	1 (0.6)
Victoria	1 (0.6)
Country of birth	
Australia	105 (66.9)
Country other than Australia	42 (26.7)
Unknown	10 (6.4)
Indigenous status	
Aboriginal or Torres Strait Islander	0 (0)
Not Indigenous	153 (97.5)
Unknown	4 (2.5)

Table 1. Cont.

Characteristics	Number of Patients (%) (n = 157)
Relationship status	
Single ^c	49 (31.2)
Partnered ^d	90 (57.3)
Unknown	18 (11.5)
Previous cannabis use	
Yes	28 (17.8)
No	1 (0.6)
Not stated	128 (81.5)
Condition class ^e and condition	
Musculoskeletal	39 (24.8) ^f
Spondylosis	25 (15.9)
Neurological	91 (58.0)
Parkinson's disease	23 (14.6)
Migraine	16 (10.2)
Multiple sclerosis	10 (6.4)
Neuropathic pain	9 (5.7)
Peripheral neuropathy	9 (5.7)
Autoimmune	14 (8.9)
Inflammatory	10 (6.4)
Other	23 (14.6)
Chronic pain syndrome	19 (12.1)
Number of conditions treated	
One	137 (87.3)
Two	19 (12.1)
Three	1 (0.6)
Indications	
Pain	136 (86.6)
Muscle spasms	18 (11.5)
Sleep	10 (6.4)
Cannabis-based medicines used	
Number	
1	112 (71.3) ^g
2	31 (19.7)
≥3	14 (8.9)
Type (route of administration)	
Oil (oral)	156 (99.4)
Flower (inhalation)	5 (3.2)
Oromucosal spray (sublingual)	1 (0.6)
Cannabinoid ratios	
CBD only ^h	22 (14.0)
CBD dominant ⁱ	5 (3.2)
Low Δ-9-THC ^j	12 (7.6)
Balanced ^k	133 (84.7)
Δ-9-THC dominant/Δ-9-THC only ^l	15 (9.6)

Table 1. Cont.

Characteristics	Number of Patients (%) (n = 157)
Cannabinoid highest dosage (mg/day)	Mean ± SD
CBD	34.8 ± 48.04 *
Δ-9-THC	16.9 ± 17.23

CBD: Cannabidiol. Δ-9-THC: Δ-9-tetrahydrocannabinol. ^a As reported in the medical notes; ^b Covers around 12,368.2 km² and 37.6% (n = 59) of patients travelled 20 km or more to access the clinic; ^c Not in a relationship, including divorced, widowed, separated; ^d In a relationship, including married, de facto, same sex; ^e For each condition class, the conditions with ≥10 patients are shown (neuropathic pain and peripheral neuropathy have been combined in the analysis); ^f Percentages for ‘Condition class’ and ‘Indications’ are given as individual frequencies out of the entire study population, as some patients had more than one condition/indication. Percentages will add to over 100; ^g Percentages for ‘CBM type’ and ‘Cannabinoid ratios’ are given as individual frequencies out of the entire study population, as some patients used more than one type and/or more than one ratio percentages will add to more than 100; ^h Ratios (Δ-9-THC:CBD) included 0:25, 0:100. ⁱ Ratios included 1:20, 2:25; ^j Ratios included 5:20; ^k Ratios included 10:10, 25:25, 12.5:12.5, 2.7:2.5, 2.5:3.75; ^l Ratios included 10:0, 20:1, 18:1, 2.5:1, 25:2. * Significantly higher p < 0.0001.

3.2. Effectiveness of Treatment—Patient-Perceived Benefit

Just over half of patients (53.5%) perceived medicinal cannabis as being ‘beneficial’ regardless of their condition/indication (Figure 1a). Patients aged <65 years perceived relatively greater benefit from medicinal cannabis treatment (56%; n = 75) compared to those aged ≥65 (51.2%; n = 82) (Figure 1b).




Figure 1. Patient-perceived benefit of medicinal cannabis treatment: (a) overall (regardless of condition or indication); (b) comparing <65 years and ≥65 years; (c) by condition; (d) by indication. NP: neuropathic pain; PN: peripheral neuropathy.

The conditions and indications with ≥10 patients were analyzed further. For the conditions, neuropathic pain/peripheral neuropathy had the highest rate of perceived benefit (66.6%), followed by Parkinson’s disease (60.9%), multiple sclerosis (60.0%), migraine (43.8%), chronic pain syndrome (CPS) (42.1%), and spondylosis (40.0%) (Figure 1c). For the indications, medicinal cannabis had the greatest perceived effect on sleep (80.0%), pain (51.5%), and muscle spasm (50.0%) (Figure 1d).

3.3. Effectiveness of Treatment—Overall Symptom Assessment Scale Scores

Figure 2 shows the trends of the scores over time in 3-month blocks, with improved scores to 3 months and general stabilization of scores to 30 months. Mixed-effects modelling showed treatment with medicinal cannabis was associated with significant changes over time for all symptom distress (except ‘nausea’) and ‘QoL’ (Table 2). Post hoc analysis showed significant score improvements across timepoints compared to baseline for: ‘breathing problems’ to 6 months; ‘bowel problems’ to 6 months; ‘fatigue’, ‘mood’, and ‘QoL’ scores to 6 months; ‘breathing problems’ to 9 months; ‘fatigue’, ‘mood’, and ‘QoL’ scores to 9 months; and ‘pain’, ‘difficulty sleeping’, ‘fatigue’, ‘mood’, and ‘QoL’ scores to 12 months (Table 2). From the scores, ‘breathing problems’, ‘nausea’, and ‘appetite’ symptoms were not causing significant distress to patients and were not analyzed further.




Figure 2. Mean symptom assessment scale scores for all patients assessing symptom distress (10 = worst) and quality of life scores (10 = best). Analysis was possible to 30 months. n: number of patients contributing data at each timepoint; QoL: Quality of life; SAS: Symptom Assessment Scale.

3.4. Conditions

3.4.1. Spondylosis

In patients with spondylosis, improved trends were observed for ‘fatigue’, ‘difficulty sleeping’, ‘mood’, and ‘QoL’ scores to 6 months; and ‘pain’ and ‘bowel problems’ to 9 months (Figure 3a). Mixed-effects modelling showed significant changes over time in all symptom scores but no significant improvements in QoL (Table 3). Post hoc analysis found significant decreases compared to baseline for: ‘mood’ and ‘fatigue’ to 6 months; and ‘pain’ and ‘difficulty sleeping’ to 9 months (Table 3).

Table 2. Symptom assessment scale scores for all patients.

p Value, F (DFn, DFd)	Pain <0.0001, F (3.7, 342) = 36			Fatigue <0.0001, F (3.8, 357) = 28			Breathing Problems 0.0035, F (3.8, 351) = 4.1			Bowel Problems <0.0001, F (3.7, 340) = 8.3			Nausea 0.1397, F (3.7, 340) = 1.8			Appetite 0.0465, F (3.5, 327) = 2.5			Difficulty Sleeping <0.0001, F (3.1, 292) = 40			Mood <0.0001, F (3.3, 303) = 14			QoL <0.0001, F (3.5, 313) = 7.5		
	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.	M	p- Value	95% CI of Diff.
Baseline (n = 140)	7.9			7.3			2.5			4.9			2.5			3.1			6.4			5.6			4.2		
3 months (n = 151)	6.0	<0.0001	1.4 to 2.3	5.5	<0.0001	1.2 to 2.3	2.0	0.0165	0.076 to 1.0	3.6	<0.0001	0.58 to 1.9	2.3	0.7853	-0.38 to 0.84	2.6	0.1852	-0.13 to 0.98	3.9	<0.0001	1.9 to 3.0	4.1	<0.0001	0.93 to 2.0	5.1	<0.0001	-1.3 to -0.45
6 months (n = 100)	5.8	<0.0001	1.5 to 2.7	5.5	<0.0001	1.3 to 2.4	1.9	0.0084	0.14 to 1.2	3.7	0.004	0.30 to 2.0	2.3	0.8621	-0.43 to 0.83	2.5	0.2511	-0.23 to 1.3	4.2	<0.0001	1.6 to 2.7	4.1	<0.0001	0.86 to 2.1	5.3	0.0001	-1.7 to -0.47
9 months (n = 81)	5.7	<0.0001	1.6 to 2.8	5.1	<0.0001	1.4 to 2.8	2.4	0.9486	-0.45 to 0.72	3.5	0.0015	0.43 to 2.2	2.2	0.7263	-0.43 to 1.0	3.0	0.9983	-0.71 to 0.86	4.1	<0.0001	1.5 to 2.9	4.2	<0.0001	0.70 to 2.1	5.0	0.0039	-1.4 to -0.22
12 months (n = 63)	5.9	<0.0001	1.4 to 2.7	5.0	<0.0001	1.5 to 3.0	2.0	0.1381	-0.11 to 1.1	4.1	0.0947	-0.09 to 1.6	2.0	0.3074	-0.27 to 1.3	3.1	0.9997	-1.1 to 0.95	4.2	<0.0001	1.2 to 3.1	4.7	0.0244	0.090 to 1.7	5.1	0.0221	-1.7 to -0.1

Analysis was possible to 12 months. Bolded, italicized, and highlighted means are statistically significant compared to baseline at $p < 0.05$ level as analyzed by Dunnett’s test. Abbreviations: CI, Confidence interval; DFn, degree of freedom for the numerator of the F ratio; DFd, degree of freedom for the denominator of the F ratio; Diff., difference; M, Mean; QoL, Quality of life.




Figure 3. Mean symptom assessment scale scores for patients with a condition assessing symptom distress (10 = worst) and quality of life scores (10 = best). (a) Spondylosis (to 15 months); (b) Parkinson’s disease (to 21 months); (c) Chronic pain syndrome (to 21 months); (d) Combined neuropathic pain and peripheral neuropathy (to 21 months); (e) Migraine (to 18 months); (f) Multiple sclerosis (to 15 months). *n* = number of patients contributing data at each timepoint; QoL: Quality of life; SAS: Symptom Assessment Scale.

3.4.2. Parkinson’s Disease

In patients with Parkinson’s disease, improved trends were observed for scores to 3 months (‘QoL’ to 6 months), with general stabilization over time (Figure 3b). Mixed-effects modelling showed significant changes over time for ‘pain’, ‘fatigue’, and ‘difficulty sleeping’ scores (Table 3). Post hoc analysis revealed significant decreases compared to baseline for: ‘pain’ and ‘mood’ at 3 months; and ‘fatigue’ and ‘difficulty sleeping’ to 12 months (Table 3).

Table 3. Symptom assessment scale scores for patients with the condition: (a) spondylosis; (b) Parkinson’s disease; (c) chronic pain syndrome; (d) neuropathic pain and peripheral neuropathy; (e) migraine; (f) multiple sclerosis.

Spondylosis ^a		Pain			Fatigue			Bowel Problems			Difficulty Sleeping			Mood			Quality of Life		
<i>p</i> -Value, F (DFn, DFd)		0.0001, F (2.3, 35) = 11			0.0039, F (2.0, 31) = 6.7			0.0260, F (1.8, 28) = 4.3			0.0037, F (1.7, 26) = 7.5			0.0192, F (2.0, 30) = 4.5			0.3216, F (2.9, 43) = 1.2		
	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	
Baseline (n = 22)	8.5			6.9			5.2			5.9			5.8			4.7			
3 months (n = 24)	6.8	0.0001	0.92 to 2.6	6.1	0.1431	−0.22 to 1.9	3.8	0.1635	−0.44 to 3.2	4.3	0.0079	0.39 to 2.7	4.4	0.0292	0.13 to 2.7	5.1	0.7412	−1.5 to 0.75	
6 months (n = 16)	6.4	0.0005	1.1 to 3.2	4.8	0.0039	0.72 to 3.5	3.5	0.2181	−0.80 to 4.2	3.7	0.0016	0.88 to 3.4	4.2	0.0295	0.16 to 3.1	5.7	0.3092	−2.7 to 0.68	
9 months (n = 11)	5.8	0.0044	1.1 to 4.4	5.5	0.1269	−0.38 to 3.1	3.4	0.2046	−0.91 to 4.6	4	0.0075	0.59 to 3.1	5.5	0.9243	−1.7 to 2.5	4.7	>0.9999	−1.8 to 1.8	
Parkinson’s disease ^b		Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
<i>p</i> -Value, F (DFn, DFd)		0.0068, F (3.4, 49) = 4.3			0.0005, F (2.9, 40) = 7.4			0.2521, F (2.1, 30) = 1.4			0.0002, F (1.6, 22) = 15			0.1228, F (2.3, 32) = 2.2			0.2160, F (2.5, 34) = 1.6		
	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	
Baseline (n = 21)	6.7			7.5			4.8			6.4			5.4			4.4			
3 months (n = 20)	4.4	0.0039	0.71 to 3.9	4.7	0.0002	1.4 to 4.4	3.1	0.0615	−0.068 to 3.5	3.3	<0.0001	1.8 to 4.4	3.7	0.0214	0.23 to 3.2	4.9	0.5842	−1.7 to 0.65	
6 months (n = 16)	4.8	0.0793	−0.19 to 4.0	5.4	0.0161	0.38 to 3.9	3.7	0.6584	−1.6 to 3.8	3.3	0.0001	1.7 to 4.4	3.9	0.0707	−0.11 to 3.1	5.7	0.1724	−3.1 to 0.46	
9 months (n = 15)	5.1	0.0917	−0.22 to 3.4	5	0.0067	0.73 to 4.4	3.3	0.1953	−0.59 to 3.6	3.4	0.0007	1.4 to 4.5	3.7	0.0791	−0.17 to 3.5	5.4	0.3543	−2.9 to 0.78	
12 months (n = 12)	4.9	0.1614	−0.58 to 4.1	4.3	0.0092	0.85 to 5.6	3.9	0.5466	−1.1 to 2.9	3.3	0.0235	0.42 to 5.8	3.8	0.1499	−0.48 to 3.7	4.6	0.9954	−2.7 to 2.2	
Chronic pain syndrome ^c		Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
<i>p</i> -Value, F (DFn, DFd)		0.0012, F (2.1, 23) = 8.8			0.0362, F (1.7, 19) = 4.2			0.7399, F (2.4, 26) = 0.36			0.0128, F (2.6, 29) = 4.6			0.0013, F (2.5, 27) = 7.5			0.1453, F (2.2, 22) = 2.1		
	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	
Baseline (n = 16)	9.1			7.1			5.1			6.4			6.1			3.7			
3 months (n = 19)	6.8	0.0052	0.67 to 3.9	5.3	0.2321	−0.80 to 4.3	4.3	0.8853	−2.4 to 4.1	3.4	0.0015	1.2 to 4.9	3.9	0.01	0.50 to 3.9	5.1	0.0293	−2.6 to −0.13	
6 months (n = 11)	7.1	0.043	0.063 to 3.8	6.5	0.6122	−0.94 to 2.2	4.5	0.94	−2.6 to 3.9	5.4	0.582	−1.5 to 3.7	4.2	0.1026	−0.39 to 4.2	4	0.9957	−2.7 to 2.2	
9 months (n = 11)	5.9	0.0031	1.3 to 5.0	4.2	0.0147	0.67 to 5.1	4.5	0.9323	−2.4 to 3.6	3.7	0.1257	−0.74 to 6.2	4	0.1444	−0.70 to 4.9	5.2	0.2037	−3.8 to 0.83	
12 months (n = 10)	7.8	0.0348	0.11 to 2.5	6.1	0.6067	−1.7 to 3.7	5.3	0.9998	−4.3 to 4.0	4.6	0.5133	−2.5 to 6.2	7.6	0.4838	−4.7 to 1.8	4	0.9806	−2.1 to 1.6	
Neuropathic pain/peripheral neuropathy ^d		Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
<i>p</i> -Value, F (DFn, DFd)		<0.0001, F (2.5, 27) = 14			0.0326, F (2.5, 26) = 3.6			0.0563, F (2.6, 29) = 2.9			0.0046, F (2.2, 24) = 6.4			0.5335, F (2.0, 22) = 0.65			0.0771, F (2.7, 29) = 2.6		
	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	
Baseline (n = 17)	8.8			6.6			4.4			6.8			4.6			4.2			
3 months (n = 18)	6.2	<0.0001	1.5 to 3.8	4.5	0.1047	−0.35 to 4.5	3	0.0273	0.14 to 2.7	4.1	0.0014	1.1 to 4.4	3.9	0.7809	−1.4 to 2.8	5.4	0.0353	−2.4 to −0.073	
6 months (n = 12)	5.2	<0.0001	2.2 to 5.1	5	0.153	−0.53 to 3.8	3	0.422	−1.3 to 4.1	4.3	0.0073	0.74 to 4.4	4.2	0.9828	−2.1 to 2.8	5.7	0.096	−3.4 to 0.25	
9 months (n = 9)	6.1	0.0038	1.1 to 4.4	4.4	0.209	−1.3 to 5.7	2.3	0.3018	−1.5 to 5.7	4.5	0.0616	−0.12 to 4.8	4.2	0.943	−1.9 to 2.7	5.2	0.3717	−3.0 to 0.94	
12 months (n = 10)	6.2	0.008	0.79 to 4.5	4.1	0.0949	−0.48 to 5.6	2.7	0.2241	−0.90 to 4.4	5	0.1147	−0.43 to 4.2	3.1	0.1474	−0.49 to 3.6	5.3	0.4064	−3.2 to 1.0	

Table 3. *Cont.*

Migraine ^e <i>p</i> -Value, F (DFn, DFd)	Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.
	0.2182, F (1.7, 19) = 1.7			0.0144, F (2.0, 23) = 5.1			0.1243, F (2.3, 27) = 2.2			0.0171, F (2.4, 27) = 4.4			0.2191, F (1.7, 18) = 1.7			0.1138, F (2.0, 20) = 2.4		
Baseline (<i>n</i> = 17)	7.9			6.9			4.3			6.4			5.7			3.8		
3 months (<i>n</i> = 18)	7.2	0.7377	−1.4 to 2.7	5.8	0.0287	0.12 to 2.2	3.4	0.4631	−0.97 to 2.8	4.2	0.0536	−0.030 to 4.4	4.8	0.2354	−0.46 to 2.3	4.6	0.3831	−2.4 to 0.72
6 months (<i>n</i> = 12)	6.9	0.1592	−0.33 to 2.3	5.5	0.0424	0.049 to 2.8	3	0.418	−1.3 to 4.0	3.9	0.0606	−0.11 to 5.1	5.3	0.909	−1.9 to 2.8	4.8	0.2834	−2.7 to 0.68
9 months (<i>n</i> = 9)	6.4	0.2864	−1.0 to 3.9	5.8	0.3116	−0.85 to 3.1	4.1	0.9874	−2.8 to 3.3	4.3	0.1356	−0.64 to 4.9	4.3	0.546	−2.0 to 4.8	4.2	0.9356	−2.8 to 2.0
Multiple sclerosis ^f	Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.
Baseline (<i>n</i> = 10)	9			9.5			3			7.5			7			3.5		
3 months (<i>n</i> = 10)	6.3	0.0859	−3.0 to 0.0	6	0.0039	−6.0 to −1.0	2.5	0.4609	−5.0 to 1.0	4.3	0.0039	−5.5 to −1.0	5	0.0195	−5.0 to 0.50	5	0.0508	0.0 to 3.0

Analysis was possible to 9 ^{a,e} and 12 ^{b-d} months. Bolded, italicized, and highlighted means are statistically significant compared to baseline at *p* < 0.05 level as analyzed by Dunnett’s test. ^f Analysis was possible to 3 months. Bolded, italicized, and highlighted medians are statistically significant compared to baseline at *p* < 0.05 level as analyzed by Wilcoxon signed-rank test. Abbreviations: CI, Confidence interval; DFn, degree of freedom for the numerator of the F ratio; DFd, degree of freedom for the denominator of the F ratio; Diff., difference.

3.4.3. Chronic Pain Syndrome

In patients with chronic pain syndrome, improved trends were observed for the scores to 3 months which generally continued to 9 months (Figure 3c). Mixed-effects modelling showed significant changes over time in scores for 'pain', 'fatigue', 'difficulty sleeping', and 'mood' (Table 3). Post hoc analysis found significant decreases compared to baseline for: 'mood' and 'difficulty sleeping' at 3 months, 'fatigue' at 9 months, 'pain' to 12 months, with improved 'QoL' scores at 3 months (Table 3).

3.4.4. Neuropathic Pain and Peripheral Neuropathy

In patients with neuropathic pain/peripheral neuropathy, improved trends were observed for 'fatigue' and 'difficulty sleeping' scores to 3 months; 'pain' and 'QoL' to 6 months; 'bowel problems' to 9 months, and mood to 12 months (Figure 3d). Mixed-effects modelling analysis showed significant changes over time in 'pain', 'fatigue', and 'difficulty sleeping' scores (Table 3). Post hoc analysis showed significant decreases compared to baseline for: 'bowel problems' at 3 months, 'difficulty sleeping' to 6 months, and 'pain' to 12 months, with improved 'QoL' scores at 3 months (Table 3).

3.4.5. Migraine

In patients with migraine, improved trends were observed for 'mood' to 3 months; 'fatigue', 'bowel problems', 'difficulty sleeping', and 'QoL' scores to 6 months, and 'pain' to 18 months (Figure 3e). Mixed-effects modelling showed significant changes over time for 'fatigue' and 'difficulty sleeping' scores (Table 3). Post hoc analysis showed significant decreases compared to baseline for 'fatigue' scores to 6 months (Table 3).

3.4.6. Multiple Sclerosis

There are downward trends for 'pain' (initially to 3 months) and 'bowel problems' (initially to 6 months) scores to 12 months, and 'fatigue', 'difficulty sleeping', and 'mood' (all initially to 3 months) to 15 months, with improvement in 'QoL' to 6 months in patients with multiple sclerosis (Figure 3f). A Wilcoxon signed-rank test showed that the 'fatigue', 'difficulty sleeping', and 'mood' scores were significantly decreased at 3 months compared to baseline (Table 3).

3.5. Indications

3.5.1. Pain

In patients with pain, improved trends were observed for all symptom scores to 3 months ('QoL' to 6 months) with general stabilization over time (Figure 4a). Mixed-effects modelling showed significant changes over time for all symptoms scores (Table 4). Post hoc analysis found significant decreases compared to baseline for: 'bowel problems' and 'mood' to 9 months; and 'pain', 'fatigue', and 'difficulty sleeping' to 12 months, with improved 'QoL' scores to 12 months (Table 4).

Table 4. Symptom assessment scale scores for patients with the indication: (a) pain; (b) muscle spasm; (c) sleep.

Pain ^a	Pain			Fatigue			Bowel Problems			Difficulty Sleeping			Mood			Quality of Life		
<i>p</i> -Value, F (DFn, DFd)	<0.0001, F (5.0, 308) = 26			<0.0001, F (5.6, 342) = 15			<0.0001, F (5.2, 316) = 5.3			<0.0001, F (4.8, 296) = 21			<0.0001, F (5.0, 305) = 6.9			0.0004, F (4.7, 279) = 4.8		
	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.	Mean	<i>p</i> -Value	95% CI of Diff.
Baseline (n = 122)	8.5			7.3			4.9			6.4			5.6			4.1		
3 months (n = 131)	6.5	<0.0001	1.5 to 2.5	5.6	<0.0001	1.0 to 2.3	3.7	0.0001	0.50 to 2.0	4	<0.0001	1.8 to 3.0	4.1	<0.0001	0.83 to 2.0	4.9	<0.0001	−1.3 to −0.40
6 months (n = 90)	6.1	<0.0001	1.9 to 3.0	5.5	<0.0001	1.2 to 2.4	3.8	0.0121	0.18 to 2.1	4.3	<0.0001	1.5 to 2.8	4	<0.0001	0.78 to 2.2	5.2	0.0003	−1.8 to −0.42
9 months (n = 72)	6	<0.0001	1.8 to 3.1	5.2	<0.0001	1.3 to 2.9	3.6	0.0049	0.31 to 2.4	4.1	<0.0001	1.5 to 3.1	4.1	<0.0001	0.63 to 2.3	5	0.0137	−1.6 to −0.13
12 months (n = 55)	6.2	<0.0001	1.6 to 3.0	5	<0.0001	1.4 to 3.1	4.1	0.1599	−0.18 to 1.8	4.1	<0.0001	1.2 to 3.4	4.7	0.092	−0.088 to 1.8	5.1	0.029	−2.0 to −0.074
Muscle spasm ^a	Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
<i>p</i> -Value, F (DFn, DFd)	0.0490, F (2.8, 28) = 3.1			0.0043, F (1.9, 19) = 7.6			0.1481, F (2.6, 26) = 2.0			0.0555, F (1.4, 14) = 3.9			0.1790, F (2.0, 20) = 1.9			0.4053, F (2.2, 21) = 0.96		
	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.	Mean	<i>p</i> -Value	95% CI of diff.
Baseline (n = 16)	6.8			7.6			5.4			5.4			4.7			4.3		
3 months (n = 17)	4.5	0.0201	0.33 to 4.2	4.8	0.0003	1.4 to 4.2	3.3	0.0978	−0.31 to 4.4	2.9	0.0028	0.89 to 4.1	3.1	0.1239	−0.34 to 3.5	5	0.3463	−2.0 to 0.51
6 months (n = 11)	4.4	0.1706	−0.90 to 5.8	6	0.1522	−0.50 to 3.6	3.4	0.1528	−0.63 to 4.6	3.5	0.0174	0.34 to 3.3	4.1	0.8001	−1.4 to 2.6	5.1	0.7777	−3.3 to 1.8
9 months (n = 10)	4.4	0.1326	−0.69 to 5.6	4.9	0.0266	0.34 to 5.1	3	0.1514	−0.80 to 5.7	3.5	0.094	−0.32 to 4.2	3.3	0.3255	−1.0 to 3.8	5.3	0.5827	−3.2 to 1.3
12 months (n = 8)	3.4	0.1348	−1.2 to 8.1	3.8	0.0072	1.5 to 6.2	2.8	0.1428	−0.99 to 6.2	3.8	0.6223	−3.1 to 6.3	3	0.2172	−1.0 to 4.4	4.9	0.9376	−3.9 to 2.8
Sleep ^b	Pain			Fatigue			Bowel problems			Difficulty sleeping			Mood			Quality of life		
	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.	Median	<i>p</i> -Value	95% CI of diff.
Baseline (n = 9)	7			8			3			7.5			7			5		
3 months (n = 9)	2	0.1406	−5.0 to 0.50	5.5	0.0391	−6.0 to 0.0	2	0.5625	−3.0 to 2.5	4	0.0117	−4.0 to −1.5	4	0.0156	−4.5 to 0.50	6	0.3281	−1.0 to 3.0

^a Analysis was possible to 12 months. Bolded, italicized, and highlighted means are statistically significant compared to baseline at $p < 0.05$ level as analyzed by Dunnett’s test. ^b Analysis was possible to 3 months. Bolded, italicized, and highlighted medians are statistically significant compared to baseline at $p < 0.05$ level as analyzed by Wilcoxon signed-rank test. Abbreviations: CI, Confidence interval; DFn, degree of freedom for the numerator of the F ratio; DFd, degree of freedom for the denominator of the F ratio; Diff., difference.




Figure 4. Mean symptom assessment scale scores for patients with an indication assessing symptom distress (10 = worst) and quality of life scores (10 = best). (A) Pain (to 30 months); (B) Muscle spasm (to 15 months); (C) Sleep (to 9 months). *n*: number of patients contributing data at each timepoint; QoL: Quality of life; SAS: Symptom Assessment Scale.

3.5.2. Muscle Spasm

In patients with muscle spasm, initial improved trends were observed for all symptom scores to 3 months; ‘pain’, ‘fatigue’, and ‘bowel problems’ to 12 months; and ‘difficulty sleeping’, ‘QoL’, and ‘mood’ to 15 months (Figure 4b). Mixed-effects modelling showed significant changes over time for ‘pain’ and ‘fatigue’ scores (Table 4). Post hoc analysis showed significant decreases compared to baseline for: ‘pain’ at 3 months, ‘fatigue’ at 3, 9, and 12 months, and ‘difficulty sleeping’ to 6 months (Table 4).

3.5.3. Sleep

In patients with sleep issues, improved trends were observed for ‘fatigue’, ‘bowel problems’, and ‘mood’ scores to 3 months; ‘difficulty sleeping’ to 6 months; and ‘pain’ and ‘QoL’ scores (initially to 3 months) to 9 months (Figure 4c). Wilcoxon signed-rank test showed ‘fatigue’ and ‘difficulty sleeping’ scores were significantly lower at 3 months compared to baseline (Table 4).

3.6. Safety and Treatment Status

The most common side effects as reported by 68 patients (43.3%, *n* = 157) were somnolence (21.0%), dry mouth (7.6%), disorientation/confusion (3.8%), intoxication (3.8%), constipation (2.5%), and dizziness (2.5%) (Figure 5a). Unsteadiness, mood swings, vivid dreams, hallucinations, delirium, paranoia, agitation, depression, erectile dysfunction, headaches, nausea, anxiety, tachycardia, and teeth grinding were experienced by three or fewer patients (<2.5%).




Figure 5. Safety and treatment status: (A) Prevalence of the six most common side effects (*n* = 65). The number of patients who reported each side effect is displayed within each column and percentages calculated from total population (*n* = 157); (B) Reasons for treatment cessation (*n* = 39). Inefficacy = no effect on condition/indication, Loss of efficacy = initial effect wore off over time.

Around 64.8% of patient treatments were ongoing at the time of data collection, whilst 22.3% had ceased treatment. The treatment status was unknown for 22.9% of patients ($n = 157$). Thirty-nine reasons were reported for treatment cessation, with the main being inefficacy (51.3%), followed by side effects (25.6%), and relief from other medications/treatment (12.8%) (Figure 5b). One patient died from disease complications unrelated to medicinal cannabis treatment.

4. Discussion

This retrospective medical record review describes the population characteristics of patients using medicinal cannabis at a clinic in Sydney, Australia and provides data on the effectiveness and safety of medicinal cannabis treatment on patient conditions and indications. In our study, the mean age of patients was higher than in international studies (40–50 years) [14–19]. In Australia, patients must have trialed mainstream therapies before their medicinal cannabis application can be approved [4]. Patients were predominantly female, consistent with previous prospective studies of non-cancer patients [14,16,20]. Most patients were from the Greater Sydney Region which agrees with another study which found 82.6% of patients lived in urban areas [21]. This is indicative of medicinal cannabis prescribers and dispensers being established in larger urban areas [22]. More than half of the patients were partnered. This may make it easier for patients to undertake daily errands, including attending medical appointments whilst on medicinal cannabis as driving with cannabis containing Δ -9-THC is illegal in Australia [23].

It difficult to ascertain the actual numbers of patients that had used cannabis before attending the clinic as patients are under no obligation to state previous cannabis use. However, the results here are similar to another Australian study which showed that 14.1% had not used cannabis before using it for medical reasons [24].

In this study, most patients were prescribed oral oil cannabis-based medicines of balanced Δ -9-THC:CBD ratios reflecting their availability for prescription in Australia [4]. This could be due to cannabis flower being very expensive and the ease of administering oils compared to vaporization [4]. In contrast, international patients predominantly inhale cannabis; however, oral preparations are becoming more prevalent due to greater physician advocacy [15,16,21,25].

Literature shows that therapeutic doses of Δ -9-THC (5–20 mg) tend to be smaller than CBD (50–1500 mg) [4] and our study supports this finding. This is expected as CBD is non-psychoactive and may circumvent the side effects of Δ -9-THC [17]. Our study showed that higher doses of Δ -9-THC were used which may indicate that people with non-cancer conditions/indications may be able to tolerate higher doses compared to people with cancer, and this needs to be ascertained in clinical use [19].

Most patients in our study sought treatment for neurological and musculoskeletal conditions, with pain as the main indication. This agrees with data indicating that most approvals in Australia are for chronic pain, and pain ranks as the number one indication in several studies [4,14,16,21]. In previous studies, the frequency of insomnia and psychiatric disorders is higher [16,18,21], with one study reporting 9.7% and 27% of patients, respectively [26]. Our study's lower incidence (1.3% and 0.6%, respectively) can be explained by the prescribing medical doctor referring patients with sleep and mental health disorders to other specialists to investigate/rule out specific causes of these conditions and measure their severity.

The presence of symptoms such as pain, fatigue, sleep difficulties, and poor mood in this study indicates high symptom burden across these chronic diseases [27,28]. For overall effectiveness, just over half of the patients believed medicinal cannabis to be 'beneficial', with mixed-effects modelling of all patients showing statistically significant improvements in all SAS scores except for nausea.

When comparing age groups, 56% of patients under <65 years found medicinal cannabis to be beneficial compared to 51.2% of patients aged ≥ 65 . A study of patients with cancer indicated that younger age was associated with the therapeutic success of medicinal

cannabis, which could indicate more tolerance to higher doses, and this may be reflected in the present study [29].

In terms of patient-perceived benefit, the results suggest that medicinal cannabis is more effective at treating neuropathic pain conditions compared to nociceptive pain conditions such as spondylosis (the lowest of all conditions/indications), findings congruent with available evidence on different pain conditions [11,30–32]. A prospective observational study in patients with chronic pain showed significant score reductions in measures of pain severity and interference in daily life over a 12-month study duration compared to baseline ($p < 0.001$), as well as significant improvements in QoL ($p < 0.05$) [14]. These results are supported by other studies which demonstrated significantly improved pain scores and QoL over time [15,16]. Within the conditions, SAS pain scores in our study showed significant pain decreases over time for spondylosis, chronic pain syndrome, and neuropathic pain/peripheral neuropathy to at least 9 months. Moreover, for pain as an indication, there were sustained significant decreases in all SAS scores to at least 9 months compared to baseline which shows an overarching effect of medicinal cannabis on other symptoms. Due to the many different pain etiologies, it is difficult to ascertain pain location and/or patient's response and tolerance to pain [33].

Medicinal cannabis was beneficial to around 60% of patients with Parkinson's disease. A systematic review of the effects of cannabis on Parkinson's disease, including RCTs and non-RCTs, reported improvements in sleep and pain, which agree with our findings [34].

For migraine, our study revealed that under half of the patients believed treatment to be beneficial, with significant SAS scores for 'fatigue' and a downward trend for 'difficulty sleeping'. One retrospective chart review analyzing migraine showed that 85.1% of patients reported a decrease in mean migraine headache frequency from 10.4 to 4.6 at follow-up ($p < 0.0001$) [25]. Similarly, archival data from an app showed migraine ratings reduced by 50% ($p < 0.001$) [35]. Another retrospective review showed improvements in headache profile, sleep, and mood [36].

Symptoms such as fatigue, pain, sleep, and mood disorders are also prevalent in multiple sclerosis [37]. In this study, 60.0% of patients with multiple sclerosis believed treatment to be beneficial, with symptoms of 'pain', 'fatigue', 'difficulty sleeping', and 'mood' as possible targets for medicinal cannabis treatment. For the indication muscle spasm, these results were comparable. A recent review supported Sativex's® (an oral spray of balanced Δ -9-THC and CBD) effectiveness on multiple sclerosis pain and spasticity, with improvements in sleep and QoL [38]. Another prospective study found 70.5% of patients reported a $\geq 20\%$ improvement in symptoms after one month [39], which agrees with our results. As Sativex was not widely used in our study, it is difficult to compare these findings to our study as predominantly oil formulations were used. However, over 80% of patients in this study used balanced formulations and our results could mirror these findings.

Poor sleep is an important symptom in chronic disease as it coincides with poor symptom control and impacts QoL [40]. Many studies treat sleep as a secondary outcome [41], with a literature review suggesting that cannabis could improve sleep in patients with chronic pain [42]. Although results for patients with sleep as an indication showed the greatest rate of perceived benefit of all indications/conditions analyzed, this data should be treated with caution due to a small sample size. Studies have shown insufficient and conflicting evidence for medicinal cannabis use in sleep disorders and suggest that the cannabinoid type, combination, dose, and route of administration need to be considered when designing RCTs [42,43]. Comparatively, our results showed significant improvement in SAS scores for 'difficulty sleeping' for spondylosis to 9 months and Parkinson's disease to 12 months, with improvements in other conditions to at least 3 months, with a downward trend for migraine. This also occurred with 'pain' and 'fatigue' (and sometimes 'mood') in the listed conditions and indications which shows that tackling one symptom with medicinal cannabis may reciprocate on another.

Medicinal cannabis was generally safe as shown by the follow-up SAS scores to 12 months for many of the conditions/indication. Moreover, dosing was tailored to each

patient (“start low, go slow” approach) by the prescribing medical doctor, thus minimizing dose-related toxicities [44]. A scoping review found that minor side effects were reported including somnolence, dizziness, and dry mouth which are congruent to this study’s findings [45]. In our study, the most reported reason for treatment cessation was perceived medicinal cannabis inefficacy followed by side effects, with our findings congruent to a prospective clinical trial [20].

The strength of this study is that patient data up to 30 months can be assessed which is longer than prospective and clinical trials [14,15]. Although missing data is unavoidable [46,47], mixed-effects modelling allowed for a valid analysis whilst reducing associated biases [13,47].

One limitation relates to the location of the study (undertaken at one clinic) which can introduce locality bias, and retrospective design of the study which limits the ability to evaluate the causality of medicinal cannabis use and improvements in symptom scores. Confounding factors may have influenced patient SAS scores. For example, a patient with spondylosis may have a higher score for their pain distress due to another developing issue. Whilst the PCOC SAS can accurately and reliably measure symptom distress in a palliative population, it lacks specific measures for many condition-specific indications e.g., mobility for Parkinson’s disease [48], number of headaches experienced by patients with migraine, etc. Moreover, SAS scores of bowel problems, mood, and QoL did not significantly improve with medicinal cannabis over time for the conditions/indications examined in this study. This could be due to these symptoms having multifaceted constructs which are not covered in the single SAS score. Thus, using specific measures, more frequently/consistently recorded, may have led to more significant results. Other limitations included differentiating between these differing pain etiologies, interpreting results in smaller samples, unclear dosing regimen, and lack of follow-up. It is not known whether this missing data can accurately reflect greater improvement and/or sustainability over time. Although the cannabis-based medicines were mostly balanced, other formulations and their effectiveness could not be determined. In addition, this study was unable to relate dose and safety, tolerance to previous use, and adverse drug-drug interactions.

5. Conclusions

This study indicates that medicinal cannabis, in a balanced formulation, may address a variety of non-cancer conditions and indications concurrently and can be safely prescribed by a medical doctor. The results can be used to guide future clinical trials which could investigate the conditions and indications identified here as sensitive to treatment. It is recommended that ‘pain’ and ‘difficulty sleeping’ (which may improve fatigue) be investigated further as treating these two symptoms may have reciprocating effects on each other, on mood, and QoL. Future studies should address how cannabinoids interact in the body and with one another in differing ratios and formulations, and include relevant patient-reported outcome measures and longer-term safety studies. It is recommended that patients are assessed individually to determine whether medicinal cannabis is an appropriate treatment option, considering the associated safety risks to potential therapeutic benefit. Understanding how medicinal cannabis can be used in mainstream medicine is crucial as it has the potential to positively impact millions of lives around the world.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jcm12041483/s1>, Table S1: All patient conditions; Table S2: All patient indications.

Author Contributions: Conceptualization, V.R.-N. and R.C.; formal analysis, M.M. and Z.L.; investigation, M.M.; resources, data curation, R.C.; writing—original draft preparation, M.M. and V.R.-N.; writing—review and editing, M.M., R.C., M.A., Z.L. and V.R.-N.; visualization, M.M. and V.R.-N.; supervision, methodology, V.R.-N., R.C. and M.A.; project administration, V.R.-N. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of St Vincent's Hospital Sydney, Australia (Approval No: 2020ETH00008; 2 March 2020).

Informed Consent Statement: Patient consent was waived as the research was deemed low risk as there are no therapeutic products being tested; there was no foreseeable risk of inconvenience and discomfort due to the confidential nature of the project and pooling of data; informed consent would be a major undertaking.

Data Availability Statement: De-identified data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Acknowledgments: Special thanks to the medical and administrative staff at Sacred Heart Health Service and Wolper Jewish Hospital for their time and assistance with medical record practices.

Conflicts of Interest: R.C. was involved in the collection of the data at the site and was not involved in the analysis. No other authors have any conflict of interest to disclose.

References

1. Pisanti, S.; Bifulco, M. Medical Cannabis: A plurimillennial history of an evergreen. *J. Cell Physiol.* **2019**, *234*, 8342–8351. [CrossRef] [PubMed]
2. Bridgeman, M.B.; Abazia, D.T. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. *P T A Peer-Rev. J. Formul. Manag.* **2017**, *42*, 180–188.
3. Baron, E.P. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: What a long strange trip it's been. *Headache J. Head Face Pain* **2015**, *55*, 885–916. [CrossRef]
4. Arnold, J.C.; Nation, T.; McGregor, I.S. Prescribing medicinal cannabis. *Aust. Prescr.* **2020**, *43*, 152–159. [CrossRef] [PubMed]
5. Inglet, S.; Winter, B.; Yost, S.E.; Entringer, S.; Lian, A.; Biksacky, M.; Pitt, R.D.; Mortensen, W. Clinical data for the use of cannabis-based treatments: A comprehensive review of the literature. *Ann. Pharmacother.* **2020**, *54*, 1109–1143. [CrossRef] [PubMed]
6. Savage, S.R.; Romero-Sandoval, A.; Schatman, M.; Wallace, M.; Fanciullo, G.; McCarberg, B.; Ware, M. Cannabis in pain treatment: Clinical and research considerations. *J. Pain* **2016**, *17*, 654–668. [CrossRef]
7. Australian Government Department of Health and Aged Care, Therapeutics Goods Administration. Accessing Medicinal Cannabis for a Patient. 16 November 2021. Available online: <https://www.tga.gov.au/accessing-medicinal-cannabis-patient> (accessed on 26 January 2023).
8. Australian Government Department of Health and Aged Care, Therapeutics Goods Administration. Medicinal Cannabis Special Access Scheme Category B Data. 19 August 2021. Available online: <https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-patient-access-data/medicinal-cannabis-special-access-scheme-category-b-data> (accessed on 26 January 2023).
9. Australian Government Department of Health and Aged Care, Therapeutics Goods Administration. Medicinal Cannabis Authorised Prescriber Scheme Data. Available online: <https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-patient-access-data/medicinal-cannabis-authorised-prescriber-scheme-data> (accessed on 26 January 2023).
10. Ministers, Australian Government Department of Health and Aged Care. \$3 Million for Research into Medicinal Cannabis Benefits. Available online: <https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/3-million-for-research-into-medicinal-cannabis-benefits#:~:text=The%20Australian%20Government%20is%20investing,effect%20management%20for%20cancer%20patients> (accessed on 26 January 2023).
11. National Academies of Sciences EaM. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*; The National Academies Press: Washington, DC, USA, 2017.
12. Daveson, B.A.; Allingham, S.F.; Clapham, S.; Johnson, C.E.; Currow, D.C.; Yates, P.; Eagar, K. The PCOC Symptom Assessment Scale (SAS): A valid measure for daily use at point of care and in palliative care programs. *PLoS ONE* **2021**, *16*, e0247250. [CrossRef]
13. Jakobsen, J.C.; Gluud, C.; Wetterslev, J.; Winkel, P. When and how should multiple imputation be used for handling missing data in randomized clinical trials—A practical guide with flowcharts. *BMC Med. Res. Methodol.* **2017**, *17*, 162. [CrossRef]
14. Safakish, R.; Ko, G.; Salimpour, V.; Hendin, B.; Sohanpal, I.; Loheswaran, G.; Yoon SY, R. Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study. *Pain Med.* **2020**, *21*, 3073–3086. [CrossRef]
15. Aviram, J.; Pud, D.; Gershoni, T.; Schiff-Keren, B.; Ogintz, M.; Vulfsons, S.; Yashar, T.; Adahan, H.-M.; Brill, S.; Amital, H.; et al. Medical cannabis treatment for chronic pain: Outcomes and prediction of response. *Eur. J. Pain* **2021**, *25*, 359–374. [CrossRef]
16. Meng, H.; Page, M.G.; Ajrawat, P.; Deshpande, A.; Samman, B.; Dominicis, M.; Ladha, K.S.; Fiorellino, J.; Huang, A.; Kotteeswaran, Y.; et al. Patient-reported outcomes in those consuming medical cannabis: A prospective longitudinal observational study in chronic pain patients. *Can. J. Anesth.* **2021**, *68*, 633–644. [CrossRef]

17. Baron, E.P. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: An update on current evidence and cannabis science. *Headache* **2018**, *58*, 1139–1186. [[CrossRef](#)]
18. Cahill, S.P.; Lunn, S.E.; Diaz, P.; Page, J.E. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. *Front. Public Health* **2021**, *9*, 626853. [[CrossRef](#)] [[PubMed](#)]
19. Kim, A.; Kaufmann, C.N.; Ko, R.; Li, Z.; Han, B.H. Patterns of medical cannabis use among cancer patients from a medical cannabis dispensary in New York State. *J. Palliat. Med.* **2019**, *22*, 1196–1201. [[CrossRef](#)]
20. Poli, P.; Crestani, F.; Salvadori, C.; Valenti, I.; Sannino, C. Medical cannabis in patients with chronic pain: Effect on pain relief, pain disability, and psychological aspects. a prospective non randomized single arm clinical trial. *Clin. Ter.* **2018**, *169*, e102–e107. [[CrossRef](#)] [[PubMed](#)]
21. Baron, E.P.; Lucas, P.; Eades, J.; Hogue, O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort: Official Journal of the Italian Society for the Study of Headaches. *J. Headache Pain* **2018**, *19*, 1–28. [[CrossRef](#)]
22. Australian Government: Australian Institute of Health and Welfare. *Rural & Remote Health*; AIHW: Canberra, Australia, 2019.
23. Perkins, D.; Brophy, H.; McGregor, I.S.; O'Brien, P.; Quilter, J.; McNamara, L.; Sarris, J.; Stevenson, M.; Gleeson, P.; Sinclair, J.; et al. Medicinal cannabis and driving: The intersection of health and road safety policy. *Int. J. Drug Policy* **2021**, *97*, 103307. [[CrossRef](#)]
24. Lintzeris, N.; Driels, J.; Elias, N.; Arnold, J.C.; McGregor, I.S.; Allsop, D.J. Medicinal cannabis in Australia, 2016: The cannabis as medicine survey (CAMS-16). *Med. J. Aust.* **2018**, *209*, 211–216. [[CrossRef](#)]
25. Rhyne, D.N.; Anderson, S.L.; Gedde, M.; Borgelt, L.M. Effects of medical marijuana on migraine headache frequency in an adult population. *Pharmacother. J. Hum. Pharmacol. Drug Ther.* **2016**, *36*, 505–510. [[CrossRef](#)] [[PubMed](#)]
26. Lucas, P.; Baron, E.P.; Jikomes, N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. *Harm Reduction J.* **2019**, *16*, 1–11. [[CrossRef](#)]
27. Tarolli, C.G.; Zimmerman, G.A.; Auinger, P.; McIntosh, S.; Horowitz, R.K.; Kluger, B.M.; Dorsey, E.R.; Holloway, R.G. Symptom burden among individuals with Parkinson disease: A national survey. *Neurol. Clin. Pract.* **2020**, *10*, 65–72. [[CrossRef](#)] [[PubMed](#)]
28. Green, R.; Cutter, G.; Friendly, M.; Kister, I. Which symptoms contribute the most to patients' perception of health in multiple sclerosis? *Mult. Scler. J. Exp. Transl. Clin.* **2017**, *3*, 2055217317728301. [[CrossRef](#)] [[PubMed](#)]
29. Schleider, L.B.-L.; Mechoulam, R.; Lederman, V.; Lederman, V.; Hilou, M.; Lencovsky, O.; Betzalel, O.; Shbiro, L.; Novack, V. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. *Eur. J. Intern. Med.* **2018**, *49*, 37–43. [[CrossRef](#)] [[PubMed](#)]
30. Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA* **2015**, *313*, 2456–2473. [[CrossRef](#)] [[PubMed](#)]
31. Deshpande, A.; Mailis-Gagnon, A.; Zoheiry, N.; Lakha, S.F. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. *Can. Fam. Physician* **2015**, *61*, e372–e381.
32. Harris, M.; Erridge, S.; Ergisi, M.; Nimalan, D.; Kawka, M.; Salazar, O.; Ali, R.; Loupasaki, K.; Holvey, C.; Coomber, R.; et al. UK Medical Cannabis registry: An analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. *Expert Rev. Clin. Pharmacol.* **2022**, *15*, 473–485. [[CrossRef](#)]
33. Bruggink, L.; Hayes, C.; Lawrence, G.; Brain, K.; Holliday, S. Chronic pain: 'Overlap and specificity in multimorbidity management'. *Aust. J. Gen. Pract.* **2019**, *48*, 689–692. [[CrossRef](#)]
34. Urbi, B.; Corbett, J.; Hughes, I.; Owusu, M.A.; Thorning, S.; Broadley, S.A.; Sabet, A.; Heshmat, S. Effects of cannabis in Parkinson's disease: A systematic review and meta-analysis. *J. Park. Dis.* **2022**, *12*, 495–508. [[CrossRef](#)]
35. Cuttler, C.; Spradlin, A.; Cleveland, M.J.; Craft, R.M. Short-and long-term effects of cannabis on headache and migraine. *J. Pain* **2020**, *21*, 722–730. [[CrossRef](#)]
36. Mechtler, L.; Bargnes, V.; Hart, P.; McVige, J.; Saikali, N. Medical Cannabis for Chronic Migraine: A Retrospective Review. *Neurology* **2019**, *92* (Suppl. 15), 3.10-015.
37. Lakin, L.; Davis, B.E.; Binns, C.C.; Currie, K.M.; Rensel, M.R. Comprehensive approach to management of multiple sclerosis: Addressing invisible symptoms—A narrative review. *Neurol. Ther.* **2021**, *10*, 75–98. [[CrossRef](#)]
38. Haddad, F.; Dokmak, G.; Karaman, R. The efficacy of cannabis on multiple sclerosis-related symptoms. *Life* **2022**, *12*, 682. [[CrossRef](#)] [[PubMed](#)]
39. Patti, F.; Messina, S.; Solaro, C.; Amato, M.P.; Bergamaschi, R.; Bonavita, S.; Bossio, R.B.; Morra, V.B.; Costantino, G.F.; Cavalla, P.; et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. *J. Neurol. Neurosurg. Psychiatry* **2016**, *87*, 944. [[CrossRef](#)] [[PubMed](#)]
40. Shapiro, C.M.; Devins, G.M.; Hussain, M.R. ABC of sleep disorders. Sleep problems in patients with medical illness. *BMJ Br. Med. J.* **1993**, *306*, 1532. [[CrossRef](#)]
41. Kuhathasan, N.; Dufort, A.; MacKillop, J.; Gottschalk, R.; Minuzzi, L.; Frey, B.N. The use of cannabinoids for sleep: A critical review on clinical trials. *Exp. Clin. Psychopharmacol.* **2019**, *27*, 383. [[CrossRef](#)] [[PubMed](#)]
42. Babson, K.A.; Sottile, J.; Morabito, D. Cannabis, cannabinoids, and sleep: A review of the literature. *Curr. Psychiatry Rep.* **2017**, *19*, 23. [[CrossRef](#)]

43. Suraev, A.S.; Marshall, N.S.; Vandrey, R.; McCartney, D.; Benson, M.J.; McGregor, I.S.; Grunstein, R.R.; Hoyos, C.M. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. *Sleep Med. Rev.* **2020**, *53*, 101339. [[CrossRef](#)] [[PubMed](#)]
44. Arnold, J. A primer on medicinal cannabis safety and potential adverse effects. *Aust. J. Gen. Pract.* **2021**, *50*, 345–350. [[CrossRef](#)] [[PubMed](#)]
45. Pratt, M.; Stevens, A.; Thuku, M.; Butler, C.; Skidmore, B.; Wieland, L.S.; Clemons, M.; Kanji, S.; Hutton, B. Benefits and harms of medical cannabis: A scoping review of systematic reviews. *Syst. Rev.* **2019**, *8*, 320. [[CrossRef](#)]
46. Bell, M.L.; Floden, L.; Rabe, B.A.; Hudgens, S.; Dhillon, H.M.; Bray, V.; Vardy, J.L. Analytical approaches and estimands to take account of missing patient-reported data in longitudinal studies. *Patient Relat. Outcome Meas.* **2019**, *10*, 129–140. [[CrossRef](#)]
47. Little, R.J.; D’Agostino, R.; Cohen, M.L.; Dickersin, K.; Emerson, S.S.; Farrar, J.T.; Frangakis, C.; Hogan, J.W.; Molenberghs, G.; Murphy, S.A.; et al. The prevention and treatment of missing data in clinical trials. *N. Engl. J. Med.* **2012**, *367*, 1355–1360. [[CrossRef](#)] [[PubMed](#)]
48. Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. *J. Neurol. Neurosurg. Psychiatry* **2008**, *79*, 368. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.